SITE015-0116

SITE015 (POL) › SITE015-0116

SITE015-0116

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-01-13

completed

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-30 (study day 159); relationship: not assessed

moderate assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 156); relationship: NOT RELATED

severe assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 132); relationship: not assessed

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 65); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-14 (study day 21); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.